Outcomes Research

Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.

Our data warehouse is the largest in the outpatient infusion industry. Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence.

Additionally, the strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.

Here is an example of one of our class-leading studies enabled by our data:

infection-incidence

Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)

Lucinda J. Van Anglen, PharmD
Thomas C. Hardin, PharmD,
Claudia P. Schroeder, PharmD, PhD
Open Forum Infect Dis (Fall 2018) 5 (suppl1): doi:10.1093/ofid/ofy210.2020

Cost Savings & Lower Resource Utilization

Our studies demonstrate that the physician office site of care provides significantly lower total costs compared to other settings. The Healix site of care program allows our external partners to maximize these cost benefits.

Successful Early Discharge and Avoided Hospitalization for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Treated with Outpatient Parenteral Antimicrobial Therapy (OPAT) Result in Healthcare Cost Savings

Presented on October 24, 2016

Robin H. Dretler, MD, FIDSA
Quyen Luu, MD
Richard C. Prokesch, MD, FACP, FIDSA
Andrew H. Krinsky, MD
H. Barry Baker, MD, FACP
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia Outpatient Treatment in a Physician Office Infusion Center (POIC)

Presented on October 7, 2015

Barry Statner, MD, CM FRCPC, FIDSA
Fernando S. Alvarado, MD, MPH, TM
Brian Metzger, MD, MPH
Richard M. Mandel, MD, FIDSA
Jorge R. Bernett, MD
H. Barry Baker, MD, FACP
Alfred E. Bacon III, MD
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

Open Forum Infect Dis (Fall 2015) 2 (suppl 1): doi:10.1093/ofid/ofv133.1017

Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs. Traditional Home Health Care (HHC)

Presented on October 8, 2014

Richard C. Prokesch, MD, FACP, FIDSA
John S. Adams, MD, FIDSA
Ramesh V. Nathan, MD
Claudia P. Schroeder, PharmD
Lucinda J. Van Anglen, PharmD
K. Dale Hooker, PharmD

Cost Savings Utilizing Outpatient Parenteral Antimicrobial Therapy (OPAT) for Treatment of Complicated Skin and Skin Structure Infections (cSSSI) in Physician Operated Infusion Centers (POICs) without Hospitalization

Presented on October 27, 2009

Lucinda J. Van Anglen, PharmD
Michael P. Dailey, MD
Andrew H. Krinsky, MD
John S. Adams, MD

Clinical Outcomes

Our physicians and clinical teams enable outstanding clinical outcomes in the physician office setting.

A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)

Published December 4, 2021

Richard L. Hengel, MD
Brian S. Metzger, MD, MPH
H. Barry Baker, MD, FACP
John S. Adams, MD
Ramesh V. Nathan, MD, FIDSA
Rishi Bhattacharyya, MD
Richard M. Mandel, MD, FIDSA
Kimberly A. Couch, PharmD, MA, FIDSA, FASHP
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

Publication: Outpatient Treatment of Osteomyelitis with Telavancin

Published July 2017

Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD
Robin H. Dretler, MD
John S. Adams, MD, FIDSA, FSHEA
Richard C. Prokesch, MD, FACP, FIDSA
Quyen Luu, MD
Andrew H. Krinsky, MD

(doi: 10.1016/j.ijantimicag.2017.01.034). It appears in The International Journal of Antimicrobial Agents, Volume 50, Issue 1, 93 – 96 (2017), published by Elsevier

Outpatient Treatment of Infective Endocarditis at Physician Office Infusion Centers (POICs): A 2-Year Analysis of Clinical and Economic Outcomes

Presented on October 24, 2016

Brian S. Metzger, MD, MPH
Richard M. Mandel, MD, FIDSA
Jorge R. Bernett, MD
Barry Statner, MD, FRCPC, FIDSA
John S. Adams, MD, FIDSA, FSHEA
Alfred E. Bacon, III, MD
Kimberly Couch, PharmD, MA, FIDSA, FASHP
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

Open Forum Infect Dis (Fall 2016) 3 (suppl 1): doi:10.1093/ofid/ofw172.823

Real-World Comparison of Arthralgias with Infliximab vs. Vedolizumab in the Treatment of Bio-Naïve Inflammatory Bowel Disease

Presented on January 23, 2020

Timothy E. Ritter, MD
Chris Fourment, MD
Samantha A. Mehta, PharmD
Lucinda J. Van Anglen, PharmD

CCFA 2020 #P100

Special Populations

Real-World Experience of Vedolizumab in Pediatric Inflammatory Bowel Disease

Presented on October 5, 2018

Annette E. Whitney, MD
Harry E. Sarles, Jr., MD, FACG
Claudia P. Schroeder, PharmD, PhD
Tracy C. Okoro, PharmD
Lucinda J. Van Anglen, PharmD

Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population

Presented on October 4, 2017

Lucinda J. Van Anglen, PharmD
Richard M. Mandel, MD, FIDSA
Ramesh V. Nathan, MD, FIDSA
Andrew H. Krinsky, MD
Quyen Luu, MD
Alfred E. Bacon, III, MD
H. Barry Baker, MD, FACP
Claudia P. Schroeder, PharmD, PhD
Kimberly A. Couch, PharmD

Persistence

Our clinicians achieve better medication adherence through our high-touch model than any other setting.

Tolerability and Persistence with Subcutaneous Immunoglobulin Provided Through Physician Clinics for the Treatment of Primary Immunodeficiencies

Presented on February 22, 2019

Richard F. Herrscher, MD, FACAAI
Tidence L. Prince, MD
Lucinda J. Van Anglen, PharmD
Claudia P. Schroeder, PharmD, PhD

New Therapies and Programs

Effective Antimicrobial Stewardship for Outpatient Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Diseases Physician Infusion Centers

Presented on November 26, 2018

Ramesh V. Nathan, MD
Richard L. Hengel, MD
Andrew H. Krinsky, MD
Thomas K. Sleweon, MD
Alfred E. Bacon III, MD
Dale Hooker, PharmD
Claudia P. Schroeder, PharmD, PhD
Kimberly A. Couch, PharmD, MA
Lucinda J. Van Anglen, PharmD

Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093.ofid/ofy210.1510

Evaluation of Bezlotoxumab in Prevention of Recurrent C. Difficile Infection: A multicenter Single-Arm Study in Office Infusion Centers

Presented on October 3, 2018

Richard L. Hengel, MD
Timothy E. Ritter, MD
Ramesh V. Nathan, MD, FIDSA
Lucinda J. Van Anglen, PharmD
Stephen W. Marcella
Kevin W. Garey, Pharm.D., M.S., FASHP

Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093/ofid/ofy210.510

Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers